Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.0
4.2
Journals
Biology
Special Issues
New Insight of Cell Mechanisms and Therapeutic Approaches in Rheumatic...
share announcement

New Insight of Cell Mechanisms and Therapeutic Approaches in Rheumatic Diseases

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Medical Biology".

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 3559

Special Issue Editors

Dr. Cristina Antinozzi

E-Mail Website
Guest Editor
Unit of Endocrinology, Department of Movement, Human and Health Sciences, University of Rome “Foro Italico”, Piazza Lauro de Bosis, 006-00135 Rome, Italy
Interests: cellular biology; cell metabolism; rheumatic diseases; systemic sclerosis; hormones; PDE5 inhibitors
Prof. Dr. Ivan Dimauro

E-Mail Website
Guest Editor
Department of Human Motor and Health Sciences, University of Rome "Foro Italico", 00135 Rome, Italy
Interests: exercise; redox homeostasis; systemic sclerosis; cellular biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Rheumatic diseases refer to a group of autoimmune and inflammatory disorders affecting joints, bones, cartilage, tendons, ligaments and muscles. These disorders affect an important fraction of the population and lead to increased health medical costs, disability and early mortality. The etiologies are complex and generally not fully understood, making the study of pathogenic mechanisms and the pharmacological approaches in these diseases a great challenge for researchers. Better characterization and understanding of the cellular and molecular events driving these disorders is critical in order to prevent the established diseases or inhibit their development, growth and worsening.

The aim of this issue “New insight of cell mechanism and therapeutic approaches in rheumatic diseases” is highlight promising researches focusing the pathogenesis, management and prevention of rheumatic diseases, including but not limited to vasculopathies, scleroderma, osteoporosis, polymyalgia rheumatica (PMR), as well as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). We welcome different types of manuscript submissions, such as original articles, narrative reviews, systematic reviews, as well as meta-analyses concerning any aspect of cellular and molecular mechanism, diagnosis and treatment regarding the main rheumatic disorders, to provide a state-of-the-art overview of this issue.

Dr. Cristina Antinozzi
Prof. Dr. Ivan Dimauro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • autoimmune diseases
  • rheumatic diseases
  • pharmacological approaches
  • cell metabolism
  • molecular mechanisms
  • inflammation
  • physical therapies
  • biomarkers
  • disease prevention
  • antibodies

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

35 pages, 861 KiB  
Systematic Review
The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
by Mohammad Amin Habibi, Samira Alesaeidi, Mohadeseh Zahedi, Samin Hakimi Rahmani, Seyed Mohammad Piri and Soheil Tavakolpour
Biology 2022, 11(12), 1767; https://doi.org/10.3390/biology11121767 - 06 Dec 2022
Cited by 5 | Viewed by 2805
Abstract
Background and aim: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare multisystem autoimmune disease developed by autoantibody production against human neutrophilic granulocytes, including proteinase-3 (PR3) and myeloperoxidase (MPO). The management of AAV patients is difficult due to the multiorgan involvement, high [...] Read more.
Background and aim: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare multisystem autoimmune disease developed by autoantibody production against human neutrophilic granulocytes, including proteinase-3 (PR3) and myeloperoxidase (MPO). The management of AAV patients is difficult due to the multiorgan involvement, high rate of relapse, and complications of immunosuppressive agents that make it challenging. This study aims to investigate the efficacy and safety of rituximab (RTX) therapy in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) subtypes. Method: The PubMed/Medline database was searched for any studies related to RTX therapy in ANCA-associated vasculitis (GPA and MPA subtypes), from inception to 1 August 2022, and proceeded in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results: Our search resulted in 1082 initial records. After the elimination of review papers, irrelevant studies, and non-English records, 223 articles were included, and the data related to the efficacy and safety of RTX therapy were extracted. Several randomized and non-randomized studies showed that RTX is an effective treatment option for patients with AAV. Most of the studies showed the very effective effect of RTX in controlling disease in AAV patients, including pediatrics, adults, and elderlies, although RTX cannot completely prevent relapse. However, maintenance therapy helps delay the disease’s relapse and causes sustained remission. Not only the licensed dose (375 mg/m2 intravenous per week for 4 weeks) could induce disease remission, but studies also showed that a single infusion of RTX could be effective. Although RTX could resolve many rare manifestations in AAV patients, there are few reports showing treatment failure. Additionally, few sudies have reported the unexpeted worsening of the disease after RTX administration. Generally, RTX is relatively safe compared to conventional therapies, but some serious adverse effects, mainly infections, cytopenia, hypogammaglobinemia, malignancy, and hypersensitivity have been reported. Conclusions: RTX is an effective and relatively safe therapeutic option for AAV. Studies on the evaluation of the safety profiles of RTX and the prevention of severe RTX-related side effects in AAV patients are required. Full article
(This article belongs to the Special Issue New Insight of Cell Mechanisms and Therapeutic Approaches in Rheumatic Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop